Company description

Cara Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative drugs for pain management and pruritus (itching). Founded in 2004, the company is headquartered in Stamford, Connecticut and has a diverse portfolio of novel drug candidates in various stages of clinical development. Cara's lead product candidate, Korsuva Injection, is currently in Phase 3 clinical trials for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP). The company also has a pipeline of other potential products, including oral and IV formulations of Korsuva, as well as a non-opioid, peripherally-acting kappa opioid agonist for the management of acute and chronic pain. Additionally, Cara has partnerships with major pharmaceutical companies, including Vifor Pharma Group and Mitsubishi Tanabe Pharma Corporation, for the development and commercialization of Korsuva in markets outside of the United States. With a strong emphasis on scientific innovation and a commitment to improving the lives of patients, Cara Therapeutics is well-positioned for future growth in the biopharmaceutical industry.